A multi-center study explored the effect of the investigational anti-cancer agent rociletinib in patients with EGFR-mutant non-small cell lung cancer.
“This is a potential game changer for lung cancer patients whose disease is driven by EGFR mutations. Previously, once tumors learned to evade treatment with first-line EGFR inhibitors, we had no second targeted treatment. With these promising results, it is looking extremely likely that we now have a therapy that will keep people alive, well and in the game,” says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the study’s senior author.
The drug rociletinib is owned by Clovis Oncology Inc, which is based in Boulder, Colo. Due to strong early results, the drug received the new FDA “Breakthrough Status” designation, developed in part by Colorado’s Senator Michael Bennet as a means to accelerate the approval process for very promising new medical treatments.
